应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SGP SpyGlass Pharma, Inc.
盘后交易 04-30 19:19:35 EDT
22.94
+0.81
+3.66%
盘后
22.94
+0.00
0.00%
16:10 EDT
最高
23.35
最低
22.48
成交量
5.68万
今开
22.48
昨收
22.13
日振幅
3.93%
总市值
7.64亿
流通市值
2.47亿
总股本
3,332万
成交额
129.95万
换手率
0.53%
流通股本
1,078万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
SpyGlass Pharma创新性Bim-Iol系统公布12个月I/II期试验积极顶线结果
美股速递 · 03-09
SpyGlass Pharma创新性Bim-Iol系统公布12个月I/II期试验积极顶线结果
异动解读 | SpyGlass Pharma纳斯达克IPO首日开盘价翻倍,盘中大涨50%
异动解读 · 02-07
异动解读 | SpyGlass Pharma纳斯达克IPO首日开盘价翻倍,盘中大涨50%
美股异动 | SpyGlass Pharma(SGP.US)登陆美股市场 开盘暴涨超43%
智通财经 · 02-07
美股异动 | SpyGlass Pharma(SGP.US)登陆美股市场 开盘暴涨超43%
加载更多
公司概况
公司名称:
SpyGlass Pharma, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
SpyGlass Pharma, Inc.根据特拉华州法律于2019年1月7日注册成立。该公司是一家处于后期阶段的生物制药公司,正在启动其先导产品的3期临床试验,这是一种IOL挂载、控释、药物递送系统,旨在通过药物比马前列素的递送来治疗青光眼。其使命是通过开发持久的药物递送解决方案来显著改善患有慢性眼病的患者的生活,这些解决方案可以让患者和外科医生对长期疾病控制和视力保护充满信心。
发行价格:
--
{"stockData":{"symbol":"SGP","market":"US","secType":"STK","nameCN":"SpyGlass Pharma, Inc.","latestPrice":22.94,"timestamp":1777579200000,"preClose":22.13,"halted":0,"volume":56837,"hourTrading":{"tag":"盘后","latestPrice":22.94,"preClose":22.94,"latestTime":"16:10 EDT","volume":303,"amount":6950.820000000001,"timestamp":1777579804146,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03660189787618628,"floatShares":10781300,"shares":33317414,"eps":-17.982468,"marketStatus":"盘后交易","change":0.81,"latestTime":"04-30 19:19:35 EDT","open":22.48,"high":23.35,"low":22.48,"amount":1299517.8872,"amplitude":0.039313,"askPrice":23.39,"askSize":85,"bidPrice":22.49,"bidSize":88,"shortable":3,"etf":0,"ttmEps":-17.982468,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1777593600000},"marketStatusCode":4,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":22.13,"preHourTrading":{"tag":"盘前","latestPrice":21.41,"preClose":22.13,"latestTime":"04:14 EDT","volume":1,"amount":21.41,"timestamp":1777536896449,"change":-0.72,"changeRate":-0.032535,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":22.94,"preClose":22.94,"latestTime":"16:10 EDT","volume":303,"amount":6950.820000000001,"timestamp":1777579804146,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.799681},"requestUrl":"/m/hq/s/SGP","defaultTab":"news","newsList":[{"id":"1158394775","title":"SpyGlass Pharma创新性Bim-Iol系统公布12个月I/II期试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1158394775","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158394775?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:01","pubTimestamp":1773057718,"startTime":"0","endTime":"0","summary":"SpyGlass Pharma公司宣布,其创新性Bim-Iol系统在为期12个月的I/II期临床试验中取得了积极的顶线结果。该数据展现了该系统在眼科治疗领域的应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173758808","title":"异动解读 | SpyGlass Pharma纳斯达克IPO首日开盘价翻倍,盘中大涨50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173758808","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173758808?lang=zh_cn&edition=full","pubTime":"2026-02-07 01:29","pubTimestamp":1770398971,"startTime":"0","endTime":"0","summary":"生物制药公司SpyGlass Pharma, Inc.今日盘中股价大幅上涨,涨幅达到50.00%,引起了市场的广泛关注。消息面上,SpyGlass Pharma今日在纳斯达克成功完成首次公开募股,开盘价达到每股32美元,远高于其16美元的发行价。此次IPO以每股15至17美元的价格区间出售了约940万股股票,共融资1.5亿美元。SpyGlass Pharma成立于2019年,专注于为慢性眼病开发长效疗法的药物输送系统。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609839513","title":"美股异动 | SpyGlass Pharma(SGP.US)登陆美股市场 开盘暴涨超43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609839513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609839513?lang=zh_cn&edition=full","pubTime":"2026-02-07 00:00","pubTimestamp":1770393633,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周五,SpyGlass Pharma(SGP.US)登陆美股市场,开盘股价暴涨超43%,报23美元,IPO价格为16美元。SpyGlass Pharma 是一家临床后期生物技术公司,专注于开发 用于慢性眼部疾病的持续药物输送系统,旨在通过更长效、可持续的治疗方案改善患者的视力和生活质量。其核心研发产品包括一种将药物输送垫与人工晶状体结合的系统,用于治疗像 开角型青光眼或眼压高 等慢性眼病。这类治疗目标是提高疗效和患者依从性,与传统每日滴眼药水相比有潜在优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IWO","BK4581","UWM","BK4550","TWM","RWM","SGP","SRTY","TNA","BK4534","IWN","TZA","BK4535","MNQmain","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.spyglasspharma.com","stockEarnings":[{"period":"1week","weight":-0.0964},{"period":"1month","weight":-0.0531},{"period":"3month","weight":0.3831},{"period":"ytd","weight":0.3831}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"SpyGlass Pharma, Inc.根据特拉华州法律于2019年1月7日注册成立。该公司是一家处于后期阶段的生物制药公司,正在启动其先导产品的3期临床试验,这是一种IOL挂载、控释、药物递送系统,旨在通过药物比马前列素的递送来治疗青光眼。其使命是通过开发持久的药物递送解决方案来显著改善患有慢性眼病的患者的生活,这些解决方案可以让患者和外科医生对长期疾病控制和视力保护充满信心。","exchange":"NASDAQ","name":"SpyGlass Pharma, Inc.","nameEN":"SpyGlass Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SpyGlass Pharma, Inc.(SGP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SpyGlass Pharma, Inc.(SGP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SpyGlass Pharma, Inc.,SGP,SpyGlass Pharma, Inc.股票,SpyGlass Pharma, Inc.股票老虎,SpyGlass Pharma, Inc.股票老虎国际,SpyGlass Pharma, Inc.行情,SpyGlass Pharma, Inc.股票行情,SpyGlass Pharma, Inc.股价,SpyGlass Pharma, Inc.股市,SpyGlass Pharma, Inc.股票价格,SpyGlass Pharma, Inc.股票交易,SpyGlass Pharma, Inc.股票购买,SpyGlass Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SpyGlass Pharma, Inc.(SGP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SpyGlass Pharma, Inc.(SGP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}